Abstract
Since the discovery of the inflammasome, interleukin 1 production has been found to be integral in the pathophysiology of gout. Interleukin 1 inhibition by Anakinra has been shown to effective for the treatment of gout. We report three cases of resistant chronic tophaceous gout who responded to anakinra subcutaneous injections on an intermittent basis.
© 2011 The Authors. International Journal of Rheumatic Diseases © 2011 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.
MeSH terms
-
Acute Disease
-
Aged
-
Allopurinol / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Chronic Disease
-
Colchicine / therapeutic use
-
Drug Resistance / drug effects
-
Gout / drug therapy*
-
Gout / metabolism
-
Gout / physiopathology
-
Gout Suppressants / therapeutic use*
-
Humans
-
Injections, Subcutaneous
-
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
-
Interleukin-1 / antagonists & inhibitors*
-
Interleukin-1 / metabolism
-
Male
-
Middle Aged
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Gout Suppressants
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-1
-
Allopurinol
-
Colchicine